Treatment options for hepatocellular carcinoma

Area of Science:

• Hepatology
• Oncology
• Molecular Biology

Background:

• Hepatocellular carcinoma (HCC) often presents at advanced stages, leading to high mortality rates.
• Rising cases worldwide are linked to improved survival in cirrhotic liver disease and increased hepatitis C prevalence.
• Early diagnosis and treatment are crucial for improving patient prognosis.

Purpose of the Study:

• To review current and emerging treatment strategies for Hepatocellular Carcinoma (HCC).
• To highlight the potential of novel molecular targeted therapies in combination with existing treatments.

Main Methods:

• Review of surgical resection, liver transplantation, and locoregional therapies (percutaneous ethanol injection, radiofrequency ablation, transcatheter arterial chemoembolization, radioembolization).
• Exploration of novel systemic therapies targeting molecular pathways involved in HCC pathogenesis.
• Analysis of recent clinical trial data, including Phase III studies of targeted agents like sorafenib.

Main Results:

• Surgical resection and liver transplantation offer potentially curative options for selected patients.
• Locoregional therapies are viable for unresectable HCC.
• Systemic therapy has historically been limited, but targeted molecular therapies show significant promise.
• Sorafenib, a receptor tyrosine kinase inhibitor, has demonstrated positive results in Phase III studies.

Conclusions:

• Combination therapies involving targeted molecular agents with surgical or locoregional approaches are expected to substantially improve outcomes for intermediate and advanced HCC.
• Targeted therapies represent a significant advancement in HCC treatment, addressing unmet needs in systemic therapy.